American Family Physician Community Blog

Lilian White, MD
Posted on November 4, 2024

https://www.aafp.org/pubs/afp/afp-community-blog/entry/management-of-pots-due-to-long-covid.html

 Linda Elsegood interviewing Andrea, a patient from the United States who has been taking low dose naltrexone (LDN) to manage her health concerns.

Experts Develop Multimodal Approach for Treating Long COVID, Other Post-Acute Infectious Syndromes
Pharmacy Times, September 13, 2024
By Luke Halpern, Assistant Editor

An international team of researchers has proposed a multimodal approach involving a mixture of physical and pharmacological interventions to treat post-acute infectious syndromes (PAIS), including the condition known as long COVID that affects survivors of SARS-CoV-2 infection, the virus that causes COVID-19.

News Medical Life Sciences
Genomic Press
Sep 4 2024

In a world still grappling with the aftermath of the COVID-19 pandemic, a team of international researchers has proposed a novel approach to treating the persistent symptoms that plague many survivors of viral infections. The study, published on 30 August 2024 in Brain Medicine (ISSN: 2997-2639, Genomic Press, New York), outlines a multimodal treatment strategy that could offer hope to millions suffering from post-acute infectious syndromes (PAIS), including the condition commonly known as Long COVID.

BY Kenny Cheng August 19, 2024

Yale Medicine

Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia

Hiten Naik et al. Online issue publication May 13, 2024

Griffith University researchers to trial naltrexone on long COVID patients

By Janelle Miles and Emma Pollard

Posted Mon 6 May 2024

https://www.abc.net.au/news/2024-05-07/qld-griffith-university-trial-naltrexone-long-covid/103800050

Jayden Donald went from a fit and healthy teenager who rode his horses almost every day, to being so sick he could hardly sit up after his second bout of COVID-19.